News / US / cnbc
Thyme Care Secures $125 Million Series E Funding at $2 Billion Valuation
cnbc · 2026-09-02
HUM, CVS
Oncology navigation startup Thyme Care has raised $125 million to launch a new parent company, Thyme Companies, aimed at addressing systemic gaps in cancer care.
What Happened
Strategic Funding Milestone: Thyme Care has successfully closed a $125 million Series E funding round, effectively doubling its valuation to over $2 billion. The round was led by Morgan Health, with significant participation from major healthcare players including Humana and CVS Health Ventures, signaling strong institutional confidence in the company's oncology navigation model.
Corporate Restructuring: The company is establishing a new parent entity, Thyme Companies, to expand its focus beyond virtual patient navigation. This move allows the firm to diversify its initiatives, with executive chairman Robin Shah leading the effort to tackle broader systemic issues in how cancer treatment is accessed and financed.
Operational Expansion Goals: Initial priorities for the new corporate structure include improving the affordability of cancer medications and streamlining clinical trial enrollment processes. By addressing these critical gaps, the company aims to reduce the financial burden on patients while accelerating the adoption of cost-effective biosimilars.
Financial Health and Future Outlook: Thyme Care has reached profitability and is now generating positive free cash flow, providing a robust balance sheet for potential future acquisitions. While management is not currently pursuing an IPO, they remain focused on long-term growth and scaling their platform to solve complex challenges within the global oncology landscape.